Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib

Saved in:
Bibliographic Details
Published inJournal of gastrointestinal cancer Vol. 50; no. 3; pp. 601 - 603
Main Authors Kongsuphon, Noppadon, Soukavanitch, Maturos, Teeraaumpornpunt, Noramon, Konmun, Jitprapa, Ativitavas, Touch, Ngamphaiboon, Nuttapong
Format Journal Article
LanguageEnglish
Published New York Springer US 15.09.2019
Subjects
Aged
Ammonia - blood
Anti-Bacterial Agents - therapeutic use
Anticonvulsants - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cancer Research
Case Report
Female
Gastroenterology
Gastrointestinal Stromal Tumors - drug therapy
Gastrointestinal Stromal Tumors - pathology
Humans
Hyperammonemia - chemically induced
Hyperammonemia - diagnosis
Hyperammonemia - drug therapy
Internal Medicine
Medicine
Medicine & Public Health
Middle Aged
Neurotoxicity Syndromes - diagnosis
Neurotoxicity Syndromes - drug therapy
Neurotoxicity Syndromes - etiology
Oncology
Phenylurea Compounds - adverse effects
Protein Kinase Inhibitors - adverse effects
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyridines - adverse effects
Pyrimidines - adverse effects
Radiotherapy
Sulfonamides - adverse effects
Sunitinib - adverse effects
Treatment Outcome
Withholding Treatment
Regorafenib
Sunitinib
Posterior Reversible Encephalopathy Syndrome
Hyperammonemic Encephalopathy
Pazopanib
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1941-6628
1941-6636
DOI:10.1007/s12029-018-0067-6